Traumatic Brain Injury Studies

Pilot Clinical Studies and Development Pathway

Pilot clinical studies have been conducted across four neurological conditions to evaluate feasibility, observational outcomes, and potential directions for further clinical research.

OVERVIEW

Traumatic Brain Injury Studies

Traumatic brain injury (TBI) often leaves patients with long-lasting problems in memory, attention, mood regulation, sleep, pain, and day-to-day function. The published studies summarized below report early clinical and neurophysiological findings suggesting that biophoton therapy may support recovery in chronic TBI, including improvements in sleep, pain, quality of life, and objective EEG biomarkers.

Published TBI Study Findings

Quantitative EEG study in chronic TBI

A published case-series study evaluated four patients with chronic TBI using resting-state quantitative EEG and event-related potential testing before treatment, during placebo exposure in some cases, and after 4 to 6 weeks of active therapy. The study tracked posterior peak frequency, theta/beta ratio, frontal alpha asymmetry, eyes-closed/eyes-open alpha ratio, ERP latencies, and Brodmann area z-scores.

The overall study reported that placebo exposure produced no measurable improvement, while active therapy was associated with consistent electrophysiological gains across patients. These included increased posterior alpha frequency, reduced theta/beta ratio, improved alpha-ratio regulation, faster ERP processing, and normalization trends in frontal, temporal, and sensorimotor brain regions.

One representative case showed especially clear longitudinal improvement after switching from placebo to active treatment. In that patient, posterior peak frequency increased from 9.3 Hz to 10.6 Hz by week 6, theta/beta ratio fell from 0.61 to 0.40, frontal alpha asymmetry returned from a negative placebo-phase shift to a positive range, and Brodmann area abnormalities in language/memory and attention/emotion regions moved closer to normal. The authors interpreted these changes as evidence of improved alertness, attention regulation, emotional tone, vigilance, and working memory.

A second case showed similar trends over four weeks of therapy, with posterior peak frequency improving from 9.4 to 10.4 Hz, theta/beta ratio dropping from 0.97 to 0.75, eyes-closed/eyes-open alpha ratio increasing from 1.56 to 1.96, and ERP measures showing faster visual, auditory, and working-memory processing. Reaction times improved across multiple sensory modalities, while source-localization findings showed reduced abnormalities in sensorimotor and emotional-regulation areas.

Taken together, this EEG-based study suggests that chronic TBI improvement may be accompanied by measurable restoration in brain-network function, not just subjective symptom change. 

Pilot study in retired NFL players with TBI

A second published pilot study focused on retired NFL players with chronic TBI-related symptoms. Twelve retired athletes used Tesla BioHealers overnight for at least 8 hours per night for an initial 60-day period, with some continuing to 120 days. Weekly interviews and biweekly surveys tracked sleep, memory, pain, energy, emotional stability, and relationships. In addition, one participant completed a blinded placebo-controlled EEG sub-study over six weeks.

The published results reported rapid and sustained changes in the athlete cohort. By the first night, all participants reportedly experienced uninterrupted sleep. By day 30, 85% reported improved cognition and reduced pain. By day 60, all participants reportedly showed full mental clarity, better physical and emotional function, and restored vitality, with sustained benefits through longer follow-up.

The placebo-controlled sub-study within this paper adds more structured evidence. During the initial two-week placebo phase, the participant reported no change in sleep, pain, medication use, or SF-36 score. After active treatment began, sleep improved, pain decreased, medication use dropped, and the SF-36 score rose from 1035 at baseline and placebo to 1345 after two weeks of treatment and 1465 after four weeks of treatment, representing a 42% improvement from baseline.

The same participant’s EEG trends also improved during active treatment. Frontal alpha asymmetry moved from a placebo-phase pattern associated with depression/anxiety risk toward a normal positive range, vigilance measures stabilized, and the authors reported improvements in mood regulation, attention, and language-memory function over the treatment period. 

Same Height Control

Consistent signals across the TBI publications

Across these two published TBI studies, several recurring findings appear:

TBI patients and former athletes reported better sleep, less pain, improved cognition, stronger emotional regulation, and better overall quality of life after active therapy. Objective EEG markers moved in favorable directions, including higher posterior alpha frequency, lower theta/beta ratio, improved frontal alpha asymmetry, improved alpha-ratio regulation, and faster ERP processing.  Placebo phases did not show comparable improvement, which strengthens the interpretation that the observed gains were associated with active exposure rather than time alone. 

Regenerative relevance

An additional published randomized placebo-controlled study, while not limited to TBI, reported that two weeks of active biophoton exposure increased circulating endogenous stem/progenitor cell populations, including a 2.7-fold rise in CD34+ cells, a 3.5-fold rise in CD133+ cells among leukocytes, and a 3.1-fold rise in CD34+/CD133+ cells. The same study also reported significant improvements in SF-36 quality-of-life scores and significant reductions in pain-related disability, with no significant placebo effect and no adverse events reported. These findings may help explain how functional recovery could be supported in chronic neurological injury. 

What these studies suggest

The published TBI studies suggest that biophoton therapy may have multimodal potential in chronic traumatic brain injury:

It may improve patient-reported outcomes such as sleep, pain, clarity, mood, energy, and daily function.

It may also influence objective neurophysiological biomarkers linked to attention, memory, processing speed, vigilance, and emotional regulation.

These findings remain preliminary, but they provide an early published basis for continued clinical investigation of a non-invasive approach to chronic TBI rehabilitation. 

Same Height Control

Conclusion

The published traumatic brain injury studies report encouraging early evidence that biophoton therapy may support recovery in chronic TBI. Across EEG-focused case studies and a pilot study in retired NFL players, the reported benefits include improved sleep, reduced pain, better quality of life, and measurable improvement in brain-function biomarkers. These studies are early-stage and small, so larger confirmatory trials are still needed, but they provide a foundation for further investigation into non-invasive biophoton-based neurorehabilitation in traumatic brain injury. 

Disclaimer: BrainHealing.com provides informational content regarding investigational neurological treatment programs and related scientific development activities. The information presented on this website is intended for investors, researchers, healthcare professionals, and potential strategic partners.

The investigational programs described on this website are under evaluation and are not offered for commercial sale. Statements on this website should not be interpreted as claims of regulatory approval, medical efficacy, or therapeutic effectiveness unless explicitly stated.

Nothing on this website constitutes medical advice. Individuals should consult qualified healthcare professionals regarding medical conditions or treatment decisions.